Search bioRxiv⌕ Search

Biology subjects

Mahmoud, K.

Publications and source records attributed to Mahmoud, K..

2 recordsLinked to original sources

Leveraging Unified Sequence-Structure Representations for Enhanced Protein Stability Prediction

Protein thermal stability, quantified by the change in Gibbs free energy ({Delta}{Delta}G) upon mutation, is critical for drug design and enzyme engineering. Current multi-modal deep learning models, despite integrating sequence, often struggle with indirect information fusion and incomplete capture of sequence-structure interactions. We introduce ProStab-Former, addressing these limitations by establishing a unified sequence-structure representation space for protein stability prediction. It leverages a frozen, multi-modal protein foundation encoder for residue-level feature extraction. Fine-tuned modules include Stability-Aware Attention Layers (SAAL) with structural prior bias and mutation-aware gating, and an Epistatic Interaction Module for multi-point mutation prediction. The model achieves superior or competitive performance, surpassing a state-of-the-art baseline. Ablation confirms SAALs critical role; strong generalization is shown across tasks including melting temperature prediction and pathogenic mutation classification. Its exceptional efficiency, predicting numerous single-point mutations in a single pass, positions it as a practical tool for high-throughput protein engineering and variant effect analysis.

bioinformatics↗

Anti-tumor effects of a novel cell penetrating peptide-based therapeutic approach to target Lactate Dehydrogenase C (LDHC) in triple negative breast cancer.

BackgroundLactate Dehydrogenase C (LDHC) is a promising candidate for therapeutic targeting thanks to its highly tumor-specific expression, immunogenicity, and pro-tumorigenic functions. Aberrant LDHC expression is associated with poor clinical outcomes in multiple cancers, including breast cancer. However, no specific LDHC inhibitors are currently available, highlighting the need for novel strategies to selectively target LDHC in tumor cells. This study explores the anti-tumor potential of cell-penetrating peptides (CPPs) to target LDHC in triple negative breast cancer (TNBC). MethodsFour CPPs were evaluated for their ability to deliver LDHC siRNA to tumor cells, including the positively charged 10R peptide (10R) and three bifunctional peptides containing the integrin v{beta}3 recognition motif Arg-Gly-Asp (RGD): 10R-RGD, cyclicRGD-10R (cRGD-10R), and internalizing RGD-10R (iRGD-10R). We characterized the physicochemical properties of all CPP:siRNA complexes, and determined their serum stability, cytotoxicity, cellular uptake, and LDHC silencing efficiency in vitro. The anti-tumor effects and cytotoxicity of cRGD-10R:siRNA and iRGD-10R:siRNA complexes were further assessed in a TNBC xenograft zebrafish model. ResultsAll four CPPs formed stable nanocomplexes with favorable safety profiles. The 10R-RGD and cRGD-10R peptides demonstrated the most efficient LDHC knockdown, reduced the clonogenic ability of TNBC cells and enhanced their treatment response to the chemotherapeutic drug olaparib in vitro. Treatment of TNBC xenograft zebrafish with 10R-RGD:siRNA and cRGD-10R:siRNA complexes significantly reduced tumor burden without inducing major toxicity. Conclusion Our findings demonstrate that CPP-based siRNA delivery provides a novel and safe approach to target LDHC, either as a monotherapy or in combination with common anti-cancer drugs, to enhance treatment outcomes.

cancer biology↗